Reid Robison

Reid Robison has a diverse work experience in the medical field. Reid is currently the Chief Clinical Officer at Numinus, a role they started in June 2022. Prior to this, they served as the Medical Director at Cedar Psychiatry and the Center for Change Treatment Programs, starting in August 2019 and August 2017 respectively. Reid also worked as a Founding Board Member at the Psychedelic Institute starting in May 2020. Additionally, Reid has held positions as a Board Member at PierianDx, Adjunct Faculty at both Brigham Young University and the University of Utah School of Medicine, and as a Physician at Intermountain Healthcare. Reid served as the Chief Medical Officer at Novamind from August 2020 to June 2022 and as the Coordinating Investigator at the Multidisciplinary Association for Psychedelic Studies (MAPS) from March 2020 to June 2021.

Reid Robison has a diverse education history. Reid completed a Fellowship in Biomedical Informatics at the University of Utah in 2009-2010 and another Fellowship in Neurodevelopmental Genetics from 2008-2009, also at the University of Utah. Prior to that, they obtained an MBA from the University of Utah - David Eccles School of Business from 2003-2005. In 2001, Reid Robison received their MD degree from the University of Utah School of Medicine, specializing in Medicine. Reid started their academic journey by earning a BS in Neuroscience and Business from Brigham Young University from 1994-2001. Additional certifications in Advanced Cardiovascular Life Support, American Board of Psychiatry and Neurology, and Pediatric Advanced Life Support have also been obtained.